WHO Prequalifies Takeda's New Second Dengue Vaccine Amid Rising Outbreaks

May 15, 2024, 05:16 PM

The World Health Organization (WHO) has prequalified Takeda Pharmaceuticals' new dengue vaccine, marking it as the second dengue vaccine approved amid rising outbreaks in the Americas. The WHO recommends the vaccine for use in children aged 6 to 16 years in areas with high dengue burden and transmission intensity. This new vaccine aims to boost the fight against dengue fever, a vector-borne disease transmitted by mosquitoes, with over 100-400 million cases reported worldwide each year.